The Sydney multicentre study of Parkinson's disease: Progression and mortality at 10 years

Journal of Neurology Neurosurgery and Psychiatry

Volumn 67, Issue 3, 1999, Pages 300-307

  Hely, Mariese A ^a   Morris, John G L ^a   Traficante, Robert ^b   Reid, Wayne G J ^a   O'Sullivan, Dudley J ^c   Williamson, Peter M ^d  

^a WESTMEAD HOSPITAL   (Australia)

^b Intstat Australia Pty   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

^d ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Bromocriptine; Mortality; Parkinson's disease

Indexed keywords

BROMOCRIPTINE; CARBIDOPA; LEVODOPA;

ADULT; AGED; ARTICLE; AUSTRALIA; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; EMPLOYMENT; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TEST; NURSING HOME; ONSET AGE; PARKINSON DISEASE; PNEUMONIA; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; SEX DIFFERENCE;

EID: 0032773661     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.67.3.300     Document Type: Article

References (52)

1. Hely MA, Morris JGL, Reid WGJ, et al. The Sydney multicentre study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. J Neurol Neurosurg Psychiatry 1994;57:903-10.
2. Clarke CE. Does levodopa therapy delay death in Parkinson's disease? A review of the evidence. Mov Disord 1995:10:250-6.
3. Poewe WH, Wenning GK. The natural history of Parkinson's disease. Neurology 1996;47(suppl 3):S146-52.
4. Louis ED, Marder K, Cote L, et al. Mortality from Parkinson's disease. Arch Neurol 1997;54:260-4.
5. Ebmeier KP, Calder SA, Crawford JR, et al. Parkinson's disease in Aberdeen: survival after 3.5 years. Acta Neurol Scand 1990;81:294-9.
6. Diamond SG, Markham CH, Hoehn MM, et al. Multi-centre study of Parkinson mortality with early versus later dopa treatment. Ann Neurol 1987;22:8-12.
7. Wermuth L, Stenager EN, Stenager E, et al. Mortality in patients with Parkinson's disease. Acta Neurol Scand 1995; 92:55-8.
8. Uitti RJ, Ahlskog JE, Maraganore DM, et al. Levodopa therapy and survival in idiopathic Parkinson's disease: Olmsted County project. Neurology 1993;43:1918-26.
9. Kurtzke JF, Murphy FM. The changing patterns of death rates in parkinsonism. Neurology 1990;40:42-9.
10. Chió A, Magnani C, Tolardo G, et al. Parkinson's disease mortality in Italy, 1951 through 1987. Arch Neurol 1993;50:149-53.
11. Lilienfeld DE, Chan E, Ehland J, et al. Two decades of increasing mortality from Parkinson's disease among the US elderly. Arch Neurol 1990;47:731-4.
12. Treves TA. Parkinson's disease mortality. Adv Neurol 1990; 53:411-15.
13. Shaw KM, Lees AJ, Stern GM. The impact of treatment with levodopa on Parkinson's disease. Q J Med 1980;49: 283-93.
14. Joseph C, Chassan JB, Koch ML. Levodopa in Parkinson's disease: a long-term appraisal of mortality. Ann Neurol 1978;3:116-18.
15. Hoehn MM. Parkinsonism treated with levodopa: progression and mortality. J Neural Transm 1983;(suppl 19):253-64.
16. Gurtis L, Lees AJ, Stern GM. Effect of L-dopa on course of Parkinson's disease. Lancet 1984;ii:211-12.
17. Duvoisin RC. The evaluation of extrapyramidal disease. In: de Ajuriguerra J, Gauthier G, eds. Monoamines noyaux gris centraux et syndrome de Parkinson. Geneva: Georg and Cie 1971:313-25.
18. Canter GJ, De la Torre R, Mier M. A method of evaluating disability in patients with Parkinson's disease. J Nerv Ment Dis 1961;133:143-7.
19. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-42.
20. Hely MA, Morris JGL, Reid WGJ, et al. Age at onset: the major determinant of outcome in Parkinson's disease. Acta Neurol Scand 1995;92:455-63.
21. Reid WGJ, Hely MA, Morris JGL, et al. A longitudinal study of Parkinson's disease: clinical and neuropsychological correlates of dementia. J Clin Neurosci 1996:3327-33.
22. World Health Organisation. Manual of the international classification of diseases, injuries, and causes of death. 9th revision. Geneva: WHO, 1978.
23. Ben-Shlomo Y, Churchyard A, Head J, et al. Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry. BMJ 1998;316:1191-6.
24. Diamond SG, Markham CH, Treciokas LJ. Long-term experience with L-dopa: efficacy, progression, and mortality. In: Birkmayer W, Hornykiewicz O, eds. Advances in parkinsonism. Basel: Editiones Roche, 1976:444-5.
25. Zumstein H, Siegfried J. Mortality among Parkinson patients treated with L-dopa combined with a decarboxylase inhibitor. Eur Neurol 1976;14:321-7.
26. Diamond SG, Markham CH, Hoehn MM, et al. An examination of male-female differences in progression and mortality of Parkinson's disease. Neurology 1990;40:763-6.
27. Kuroda K, Tatara K, Takatorige T, et al. Effects of physical exercise on mortality in patients with Parkinson's disease. Acta Neurol Scand 1992;86:55-9.
28. Rajput AH, Offord KP, Beard CM, et al. Epidemiology of parkinsonism: incidence, classification, and mortality. Ann Neurol 1984;16:278-82.
29. Ben Schlomo Y, Marmot MG. Survival and cause of death in Parkinson's disease: possible clues to aetiology. New Trends in Clinical Neuropharmacology 1994;8:143.
30. Morens DM, Davis JW, Grandinetti A, et al. Epidemiologic observations on Parkinson's disease: incidence and mortality in a prospective study of middle aged men. Neurology 1996;46:1044-50.
31. Parkinson Study Group. Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Ann Neurol 1998;43:318-25
32. Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4.
33. Roos RAC, Jongen JCF, Van der Velde EA. Clinical course of patients with idiopathic Parkinson's disease. Mov Disord 1996;11:236-242.
34. Gorell JM, Johnson CC, Rybicki BA. Parkinson's disease and its comorbid disorders: an analysis of Michigan mortality data, 1970-90 Neurology 1994;44:1865-8.
35. Jansson B, Jankovic J. Low cancer rates among patients with Parkinson's disease. Ann Neurol 1985;17:505-9.
36. Rajput AH, Offord KP, Beard M, et al. A case-control study of smoking habits, dementia and other illnesses in idiopathic Parkinson's disease. Neurology 1987;37:226-32.
37. Uitti RJ, Rajput AH, Ho M, et al. Parkinsonism survival in the levodopa era [abstract]. Neurology 1991;41(suppl 1):190.
38. Marder K, Mirabella E, Chen J, et al. Death rates among demented and non-demented patients with Parkinson's disease [abstract]. Ann Neurol 1990;28:295.
39. Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995:38:771-7.
40. Przuntek H, Welzel D, Blümmer E, et al. Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: prado-study discontinued. Eur J Clin Pharmacol 1992;43:357-63.
41. Goetz CG, Stebbins GT. Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology 1995;45:669-71.
42. Peterson GM, Nolan BW, Millingen KS. Survey of disability that is associated with Parkinson's disease. Med J Aust 1988;149:66-70.
43. Blin J, Dubois B, Bonnet AM, et al. Does aging aggravate Parkinsonian disability? J Neurol Neurosurg Psychiatry 1991;54:780-82.
44. Fearnley JM, Lees AJ,. Aging and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283-301.
45. Lee CS, Schuber M, Mak EK, et al. Clinical observations on the rate of progression of idiopathic Parkinsonism. Brain 1994;117:501-7.
46. Goetz CG, Tanner CM, Stebbins GT, Buchman AS. Risk factors for progression in Parkinson's disease. Neurology 1988;38:1841-4.
47. Pederzoli M, Girotti F, Scigliano G, et al. L-dopa long-term treatment in Parkinson's disease: age-related side effects. Neurology 1983;33:1518-22.
48. Jankovic J, McDermott M, Carter J, et al. Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. Neurology 1990;40:1529-34.
49. Golbe LI. Young onset Parkinson's disease: a clinical review. Neurology 1991;41:168-73.
50. Barbeau A. Six years of high-level levodopa therapy in severely akinetic parkinsonian patients. Arch Neurol 1976; 33: 333-8.
51. Martilla RJ, Rinne UK, Surtola T, et al. Mortality of patients with Parkinson's disease treated with levodopa. J Neurol 1977;216:147-53.
52. Australian Social Trends 1998. Australian Bureau of Statistics. Canberra: Australian Government Printer, 1998. Catalogue No 4102.0.